The great divide between basic drug research and clinical outcomes is being ever-more scrutinized. As we reach greater technological heights in drug development, with new drug formats and biological agents becoming the new normal, the translational capabilities of traditional in vitro and in vivo models becomes ever more strained. The expression of human drug targets, enzymes, transporters and interacting proteins on appropriate tissues becomes crucial to the successful assessment of a drug candidate. Without them, candidates are likely to be incorrectly categorized, and either put forward at risk or wrongly removed from the pipeline in vitro.

Here, we present the use of the PhysioMimix OOC System in developing human and preclinical animal microphysiological systems to decrease the divide between in vitro, in vivo and the clinic in DILI risk assessments. These systems offer the ultimate translation tool to allow greater confidence in progressing candidates to successful clinical trials.

• Determine how human and preclinical animal liver MPS are applied to predicting DILI risk
• Understand the current challenges in translation in drug development.
• Identify where MPS/OOC best fit within the drug discovery and development pipeline and how they are most suitably applied.
• Learn about the PhysioMimix human and preclinical animal liver MPS models and how they recapitulate the functionality of the liver.